Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Leerink Partners Analyst Initiates Coverage on Align Technology with Market Perform Rating and 310 Price Target

Elaine Mendonca by Elaine Mendonca
February 26, 2024
in Breaking News
0
Finance_Commercial
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter

On February 26, 2024, Michael Cherny, an analyst at Leerink Partners, began covering Align Technology (NASDAQ: ALGN) with a Market Perform rating and set a Price Target of $310 for the stock. Align Technology is renowned for its innovative Invisalign® System, a cutting-edge clear aligner system used by over 15.7 million individuals worldwide to improve their smiles. Additionally, the company offers the iTero Element™ Family of Intraoral Scanners, which improve the patient experience and enhance clinical accuracy in dental practices. Align Technology is committed to developing technology that empowers individuals to achieve the smile they have always wanted.

Align Technology Inc. (ALGN) Stock Price Drops Slightly on February 26, 2024: What to Expect Next

On February 26, 2024, Align Technology Inc. (ALGN) experienced a slight drop in its stock price. The stock opened at $314.06, which was $2.81 lower than its previous close. Throughout the trading day, the price of ALGN shares decreased by $5.58, resulting in a 1.76% drop in value.

Despite this decrease, ALGN is still performing relatively well compared to its 52-week range. The stock is currently trading in the middle of its 52-week range and is above its 200-day simple moving average. This indicates that ALGN has been relatively stable in terms of price momentum and is not experiencing any significant fluctuations.

Investors may be keeping an eye on ALGN to see how the stock performs in the coming days. While the slight drop in price on February 26 may be a cause for concern for some investors, the overall stability of ALGN’s price momentum and its position above the 200-day moving average could be seen as positive indicators for the stock’s future performance.

Align Technology, Inc. (ALGN) Stock Shows Strong Performance on February 26, 2024

On February 26, 2024, Align Technology, Inc. (ALGN) stock showed a strong performance based on the financial data provided by CNN Money. The company reported a total revenue of $3.86 billion for the past year, with a quarterly revenue of $956.73 million. In terms of net income, Align Technology reported a net income of $445.05 million for the past year, with a quarterly net income of $124.01 million. Furthermore, the earnings per share (EPS) for Align Technology stood at $5.81 for the past year, with a quarterly EPS of $1.64. Overall, Align Technology’s financial performance on February 26, 2024, was strong, with increases in total revenue, net income, and EPS compared to the previous year. Investors may view these positive financial indicators as a sign of the company’s continued growth and profitability, potentially leading to a positive impact on ALGN stock performances.

Tags: ALGN
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Mining technology

Title Trust Stamp Achieves Milestone with Utility Patent for Facial Recognition Technology

Food Producers Trading online

Pilgrims Pride Stock Soars on Strong Q4 Earnings

NRx Pharmaceuticals Launches HOPE Therapeutics Inc at BIO CEO Investor Conference 2024

Recommended

Anticipating Navigator Holdings Quarterly Earnings Report Analysts Predict 030 EPS

2 years ago
Sandy Spring Stock

Sandy Spring Bancorp’s Final Chapter: A New Era Under Atlantic Union

3 months ago
Certara Stock

Certara Stock: Regulatory Milestone and Strong Fundamentals Fuel Recovery Hopes

6 months ago
Meta Stock

Meta Faces Mounting Pressure from Regulators and Strategic Shifts

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

TCG BDC Investors Await Key Financial Milestones

Navigating Change: Schnitzer Steel’s Digital and Structural Evolution

Akso Health Group Pivots to Oncology with Global Patient Initiative

Trending

Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

by Kennethcix
February 6, 2026
0

Deluxe Corporation is successfully shedding its legacy identity as a check-printing specialist. The company's strategic pivot toward...

Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026
Vir Biotechnology Stock

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

February 6, 2026
Tellurian Stock

Tellurian Acquisition Finalized as Woodside Takes Control

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Deluxe Stock Gains Momentum on Successful Fintech Transition
  • Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches
  • Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com